DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/xvg9rk/breaking_the_gene) has announced the addition of GlobalData's new report "Breaking the Gene Therapy Barrier for Life-Threatening Red Blood Cell Disorders" to their offering.

Breaking the Gene Therapy Barrier for Life-Threatening Red Blood Cell Disorders takes a look at gene therapy for the treatment of blood disorders such as beta-thalassemia and sickle cell anemia. An international team of researchers led by scientists at Weill-Cornell Medical College in New York City have designed a novel gene therapy strategy with potentially curative implications for patients with beta-thalassemia and sickle cell anemia. This development represents an important advance in addressing significant unmet market needs regarding the future development of therapeutic products for these two serious red blood cell disorders.

Scope

- Introduction and detail on two red blood cell disorders - sickle cell anemia and beta-thalassemia

- Current gene therapy initiatives for beta-thalassemia and sickle cell anemia

- Challenges to Gene Therapy

- Market Implications

Reasons to buy

- Understand the effectiveness of gene therapy in the treatment of red blood cell disorders

Continued here:
Research and Markets: Breaking the Gene Therapy Barrier for Life-Threatening Red Blood Cell Disorders

Comments are closed.